You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Harvard Business School
Dow
McKesson

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020114


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 020114 describes ASTELIN, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from two suppliers. Additional details are available on the ASTELIN profile page.

The generic ingredient in ASTELIN is azelastine hydrochloride. There are twelve drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride profile page.
Summary for 020114
Tradename:ASTELIN
Applicant:Mylan Speciality Lp
Ingredient:azelastine hydrochloride
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020114
Suppliers and Packaging for NDA: 020114
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ASTELIN azelastine hydrochloride SPRAY, METERED;NASAL 020114 NDA Meda Pharmaceuticals 0037-0241 0037-0241-30 1 BOTTLE, SPRAY in 1 BOX (0037-0241-30) > 200 SPRAY, METERED in 1 BOTTLE, SPRAY
ASTELIN azelastine hydrochloride SPRAY, METERED;NASAL 020114 NDA Wallace Pharmaceuticals Inc. 51525-0294 51525-0294-3 1 BOTTLE, SPRAY in 1 BOX (51525-0294-3) > 200 SPRAY, METERED in 1 BOTTLE, SPRAY
Paragraph IV (Patent) Challenges for 020114
Tradename Dosage Ingredient NDA Submissiondate
ASTELIN SPRAY, METERED;NASAL azelastine hydrochloride 020114 2005-11-14

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrengthEQ 0.125MG BASE/SPRAY
Approval Date:Nov 1, 1996TE:ABRLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKesson
Merck
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.